Systematic review and meta-analysis of Chinese herbal medicine as adjuvant treatment in advanced non-small cell lung cancer patients.

CONCLUSIONS: Our study found that higher ORR, DCR, QOL, mST and 1-year OS rate were associated with CHM use as an adjuvant to chemotherapy. Although these results require further confirmation, CHMs apparently have potential therapeutic value for patients with advanced NSCLC. PMID: 32951722 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32951722?dopt=Abstract

Source: Complementary Therapies in Medicine - July 31, 2020 Category: Complementary Medicine Authors: Wang LC, Chang YY, Lee IC, Kuo HC, Tsai MY Tags: Complement Ther Med Source Type: research